{"DataElement":{"publicId":"3158824","version":"1","preferredName":"Person Prior Treatment Regimen Complete Clinical Trial Eligibility Criteria Ind-3b","preferredDefinition":"an indicator that can have a value of yes, no, or not applicable related to a person having completed a prior therapy regimen as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"3158823v1.0:2018259v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3158823","version":"1","preferredName":"Person Prior Treatment Regimen Complete Clinical Trial Eligibility Criteria","preferredDefinition":"information related to a person having completed a prior therapy regimen as an elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3158821v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3158821","version":"1","preferredName":"Prior Treatment Regimen Complete Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order.:A treatment plan that specifies the dosage, the schedule, and the duration of treatment.:A means of finding a solution to a problem, or a means of finding agreement or harmony.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25629:C15697:C75906:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Resolution","conceptCode":"C75906","definition":"A means of finding a solution to a problem, or a means of finding agreement or harmony.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94DD4C9F-D0AC-E260-E040-BB89AD4364AF","latestVersionIndicator":"Yes","beginDate":"2010-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-12","modifiedBy":"ONEDATA","dateModified":"2010-11-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94DD4C9F-D0BD-E260-E040-BB89AD4364AF","latestVersionIndicator":"Yes","beginDate":"2010-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3170966","version":"1","preferredName":"Eligibility Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"3170966v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7858-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7862-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"},{"value":"NA","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3170967","version":"1","preferredName":"Not Applicable","longName":"3170967","preferredDefinition":"Determination that a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CE1289-786C-BF60-E040-BB89AD437833","latestVersionIndicator":"Yes","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7884-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CE1289-7843-BF60-E040-BB89AD437833","latestVersionIndicator":"Yes","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"REEVESD","dateModified":"2012-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104903","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000427","version":"1","longName":"GOG-0170R","context":"NRG"},{"publicId":"10000426","version":"1","longName":"GOG-0170R","context":"NRG"}]},{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]},{"publicId":"6147165","version":"1","longName":"Wake Forest Baptist Medical Center","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6147167","version":"1","longName":"WFB","context":"NCIP"}]},{"publicId":"6162769","version":"1","longName":"University of Rochester","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6337044","version":"1","longName":"URCC Forms","context":"NCIP"}]}],"AlternateNames":[{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"PtPriTxEligIND","type":"COG GDE Short Name","context":"COG"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PrImetelstatIND","type":"COG GDE Short Name","context":"COG"},{"name":"3158823v1.0:2018259v1.0","type":"USED_BY","context":"NRG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"NCIP","type":"USED_BY","context":"NCIP"},{"name":"PtPriEligIND","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Prior therapy completed >=4 w","type":"Preferred Question Text","description":"Prior therapy completed >=4 weeks prior to enrollment on protocol (at least six weeks out from nitrosoureas and mitomycin C) and associated toxicities resolved to eligibility levels.","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Pre-treatment requirements:\r\na.\t<=2 prior hormonal treatments in any setting\r\nNote: For premenopausal patients prior therapy must have included tamoxifen.\r\nNote: For postmenopausal patients prior therapy must have included an aromatase inhibitor (AI).\r\nb.\tNo prior chemotherapy for metastatic disease.\r\nNote: Prior chemotherapy allowed in neoadjuvant and/or adjuvant setting only.\r\nc.\tNo prior lung radiation therapy.\r\nNote: Chest wall radiation for breast cancer is allowed.\r\n","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Has all therapy with nitrosoureas or Mitomycin been discontinued for at least six weeks prior to registration?","url":null,"context":"CTEP"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Has patient received prior therapy with ibrutinib?","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Did patient receive prior treatment with imetelstat?","url":null,"context":"COG"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Did patient receive > 2 prior chemotherapy regimens?","url":null,"context":"PBTC"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has patient received prior treatment with any cytotoxic chemotherapy for either the current diagnosis of T-ALL, T-LLy or for any cancer diagnosis?","url":null,"context":"CTEP"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Has patient received any prior chemotherapy (excluding steroids) and/or radiation therapy prior to this enrollment?","url":null,"context":"COG"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Prior use of ibrutinib","url":null,"context":"Alliance"},{"name":"CRF Text 6","type":"Alternate Question Text","description":"Has the patient completed prior therapy with nitrosoureas at least 6 weeks prior to registration?","url":null,"context":"CTEP"},{"name":"CRF Text 7","type":"Alternate Question Text","description":"Does the patient have a prior history of T-LBL/T-ALL?","url":null,"context":"CTEP"},{"name":"NRG_eCRF_Text _1","type":"Alternate Question Text","description":"Has hormonal therapy been completed at least 3 weeks prior to registration?","url":null,"context":"NRG"},{"name":"NRG_eCRF_Text _2","type":"Alternate Question Text","description":"Has hormonal therapy been completed at least 3 weeks prior to Step 1 registration?","url":null,"context":"NRG"},{"name":"CRF Text 8","type":"Alternate Question Text","description":"Did the patient complete appropriate institutional neoadjuvant chemotherapy?","url":null,"context":"CTEP"},{"name":"WF1804","type":"Alternate Question Text","description":">= 6 months post-potentially curative cancer treatment for breast, prostate, colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas. Ongoing hormonal therapies such as tamoxifen, aromatase inhibitors, or androgen deprivation are allowed.","url":null,"context":"NCIP"},{"name":"NRG_eCRF_Text_3","type":"Alternate Question Text","description":"Was hormone therapy discontinued at least 28 days prior to enrolment?","url":null,"context":"NRG"},{"name":"WF-1805CD","type":"Alternate Question Text","description":"Completed chemotherapy and/or radiation therapy (with or without surgery) for head and neck squamous cell carcinoma <= 6 months prior to enrollment.","url":null,"context":"NCIP"},{"name":"Have completed treatment with a platinum agent, taxane, vinca alkaloid, or bortezomib at least 3 months prior to registration. (See Appendix 1 for a list of drugs included in these drug classes).","type":"Alternate Question Text","description":"Have completed treatment with a platinum agent, taxane, vinca alkaloid, or bortezomib at least 3 months prior to registration. (See Appendix 1 for a list of drugs included in these drug classes).","url":null,"context":"NCIP"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Has patient completed curative therapy (surgery and/or radiation and/or chemotherapy) within past 12 months at a COG institution?","url":null,"context":"COG"},{"name":"CRF Text 9","type":"Alternate Question Text","description":"Was hormone therapy discontinued within 2 weeks of study registration?","url":null,"context":"NRG"},{"name":"WF-1901 v3","type":"Alternate Question Text","description":"Patients who are no longer receiving anticancer therapy must be <= 5 years since the completion of their anticancer therapy (e.g., time since the last day of chemotherapy administration, time since last day of radiotherapy, etc.).","url":null,"context":"NCIP"},{"name":"WF-1805CDv2","type":"Alternate Question Text","description":"Completed chemotherapy and/or radiation therapy (with or without surgery) for head and neck squamous cell carcinoma <= 12 months prior to enrollment.","url":null,"context":"NCIP"},{"name":"Has patient received any prior chemotherapy (excluding steroids) and/or radiation therapy for rhabdomyosarcoma prior to this enrollment?","type":"Alternate Question Text","description":"Has patient received any prior chemotherapy (excluding steroids) and/or radiation therapy for rhabdomyosarcoma prior to this enrollment?","url":null,"context":"COG"},{"name":"CRF Text10","type":"Alternate Question Text","description":"Has the patient completed 6 weeks of placebo treatment?","url":null,"context":"Alliance"},{"name":"NRG_eCRF_Text_4","type":"Alternate Question Text","description":"Has the patient completed prior therapy with nitrosoureas at least 6 weeks prior to Step 2 registration?","url":null,"context":"NRG"},{"name":"CRF Text11","type":"Alternate Question Text","description":"Chemotherapy for non-metastatic disease (e.g., adjuvant therapy) or immunotherapy for locally advanced Stage III disease","url":null,"context":"Alliance"},{"name":"Completed chemotherapy and/or radiation therapy (with or without surgery) with curative intent for head and neck squamous cell carcinoma <= 24 months prior to designated clinician visit.","type":"Alternate Question Text","description":"Completed chemotherapy and/or radiation therapy (with or without surgery) with curative intent for head and neck squamous cell carcinoma <= 24 months prior to designated clinician visit.","url":null,"context":"NCIP"},{"name":"Did the patient receive prior chemotherapy and/or radiation therapy for cancer prior to enrollment?","type":"Alternate Question Text","description":"Did the patient receive prior chemotherapy and/or radiation therapy for cancer prior to enrollment?","url":null,"context":"COG"},{"name":"COG CRF text 05","type":"Alternate Question Text","description":"Within 12 months before the planned initial COVID-19 vaccine dose, has patient received one of the cancer treatments?","url":null,"context":"COG"},{"name":"COG CRF text 6","type":"Alternate Question Text","description":"Prior to the initial planned COVID-19 vaccine dose, is the patient undergoing or has the patient previously received one of the cancer treatments within the past 12 months?","url":null,"context":"COG"},{"name":"WF1804CD-AH-HA","type":"Alternate Question Text","description":"Greater than or equal to 6 months post-potentially curative cancer treatment for breast, prostate, colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas.  Ongoing hormonal therapies such as tamoxifen, aromatase inhibitors (with or without adjuvant CDK 4/6 inhibitors such as abemaciclib), or androgen deprivation are allowed.","url":null,"context":"Training"},{"name":"NRG CRF_Text_1","type":"Alternate Question Text","description":"Has prior therapy been completed at least four weeks prior to registration?","url":null,"context":"NRG"},{"name":"CRF text12","type":"Alternate Question Text","description":"Prior chemotherapy for non-metastatic disease (e.g., adjuvant therapy) for locally advanced Stage III disease?","url":null,"context":"Alliance"},{"name":"COG CRF text 7","type":"Alternate Question Text","description":"Is the patient undergoing or has the patient previously received one of the cancer treatments within the 12 months before their first COVID-19 vaccine dose?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"94DD4C9F-D0CE-E260-E040-BB89AD4364AF","latestVersionIndicator":"Yes","beginDate":"2010-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-11-12","modifiedBy":"TYRRELLM","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":"8/16/2023 added AQT and Alt Short Name per cadsr0002745_mmt\r\n6/14/2023: added AQT per cadsr0002525.wz","unresolvedIssues":null,"deletedIndicator":"No"}}